Ionis Pharmaceuticals Inc (IONS) stock
Close on Nov 11, 2026Market cap $4.71BP/E –Yield –
Ionis Pharmaceuticals Inc saw revenue fall 0.7% to $960.09M over the twelve months to Sep 30, 2026. Free cash flow was -$616.26M. At the latest close the market valued the company at $4.71B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.71B
- P/E ratio
- –
- Price to sales
- 4.90
- Price to book
- 11.96
- Dividend yield
- –
- Free cash flow yield
- -13.09%
Fundamentals
- Revenue
- $960.09M
- Net income
- -$546.54M
- EPS, diluted
- -$3.32
- Free cash flow
- -$616.26M
- Book value per share
- $2.37
- Diluted shares
- 166M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $28.19
- Open
- $28.60
- Day's range
- $28.25 – $29.42
- Volume
- 6,552,104
- Average volume (20 days)
- 4,200,443
- Index membership
- Russell 1000, Russell 3000
- Beta (5 years)
- 0.69
- 52-week range
- $27.75 – $86.74
- RSI (14 days)
- 18.0
- Volatility (1 year)
- 48.3%
- Relative volume
- 1.74×
- WACC
- 8.3%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IONS | S&P 500 | Difference | IONS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.4% | -2.4% | −35.0 pts | ||
| 3 months | -48.9% | -1.2% | −47.7 pts | ||
| Year to date | -64.2% | +12.3% | −76.5 pts | ||
| 1 year | -60.9% | +12.4% | −73.3 pts | ||
| 3 years | -38.9% | +78.8% | −117.7 pts | -15.1% | +21.4% |
| 5 years | -15.6% | +75.2% | −90.8 pts | -3.3% | +11.9% |
| 10 years | -33.5% | +311.1% | −344.6 pts | -4.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ionis Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Update
About Ionis Pharmaceuticals
Pharmaceutical Preparations
Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and delivers RNA-targeted medicines to treat serious and life-threatening human diseases. Its core therapeutic focus areas include neurology, cardiometabolic disorders, and select areas of high unmet patient need. The company's marketed product portfolio features therapies such as Tryngolza, Dawnzera, Wainua, Spinraza, Qalsody, Tegsedi, and Waylivra. These treatments serve patients suffering from severe conditions, including familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis polyneuropathy, spinal muscular atrophy, and amyotrophic lateral sclerosis. In addition to commercializing products independently in select markets, the company partners with global pharmaceutical firms to co-develop and distribute its therapies worldwide.
Company profile, executives and historyIonis Pharmaceuticals stock: common questions
What is Ionis Pharmaceuticals's stock price?
IONS closed at $28.33 on Nov 11, 2026, up 0.50% on the day. Over the past 52 weeks it traded between $27.75 and $86.74.
What is Ionis Pharmaceuticals's market cap?
Ionis Pharmaceuticals was worth $4.71B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IONS's P/E ratio?
Ionis Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.32), so it has no meaningful P/E ratio.
How much revenue does Ionis Pharmaceuticals make?
Ionis Pharmaceuticals reported revenue of $960.09M for the twelve months to Sep 30, 2026, down 0.7% from a year earlier.
Does Ionis Pharmaceuticals pay a dividend?
No. Ionis Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Ionis Pharmaceuticals report earnings next?
Ionis Pharmaceuticals is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IONS stock performed over the past year?
Including dividends, IONS returned -60.9% over the past year, against +12.4% for the S&P 500.
How many IONS shares are sold short?
21M shares were sold short at the latest FINRA report, 12.84% of the float, or 8.4 days of average trading volume.
Who are Ionis Pharmaceuticals's competitors?
Companies most similar to Ionis Pharmaceuticals by business, industry and size include PTCT, ARWR, INSM, BBIO, CORT.
See a number that looks wrong?